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The essential oil of Thymus vulgaris L. (Lamiaceae), thyme oil, shows a great variability 
of its composition with six main chemotypes recognized up to now: geraniol, linalool, -
terpineol, carvacrol, thymol, and trans-thujan-4-ol/terpinen-4-ol types. Due to this large 
chemical diversity, the subject of several investigations was to identify and determine 
their properties, including their potential effect on inflammation. In our previous 
microbiological study, this essential oil showed a significant antibacterial activity against 
bacteria of the respiratory tract [1]. 
The present research focuses on the evaluation of its cytotoxic and 
antiinflammatory effect in the case of the U937 human monocyte/macrophage cell line. 
Thyme oil composition was determined by GC/MS. Bürker chamber was used for cell 
counting and flow-cytometry to evaluate cellular toxicity (using 7-AAD). Then a qPCR 
method was used to determine the expression of TNFα mRNA. 
The main component of the tested sample of thyme oil was thymol (38.7%) that 
showed a concentration-dependent cytotoxicity. Non-toxic dilutions showed preventive 
antiinflammatory potential. 
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